Irene López-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Irene López-Rodríguez has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Cesar Fabián Reyes-Manzano
Tecnológico Nacional de México, Tecnológico de Estudios Superiores de Ixtapaluca, Km. 7 Carretera Ixtapaluca-Coatepec S/N San Juan, Ixtapaluca, Estado de México 56580, Mexico
2 shared publications - Lev Guzmán-Vargas
Laboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Ciudad de México 07340, Mexico
2 shared publications - Ariel Guzmán-Vargas
Laboratorio de Investigación en Materiales Porosos, Catálisis Ambiental y Química Fina, Instituto Politécnico Nacional, ESIQIE-SEPI-DIQI, UPALM Edif. 7 P.B. Zacatenco, GAM, CDMX 07738, Mexico
1 shared publication - Israel Reyes-Ramírez
Laboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Ciudad de México 07340, Mexico
1 shared publication - Tania Jetzabel Contreras Uribe
Tecnológico de Estudios Superiores de Ixtapaluca
1 shared publication
Latest Publications
- Open Access
The Complex Structure of the Pharmacological Drug–Disease Network
The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures).
Open AccessThe Complex Structure of the Pharmacological Drug–Disease Network
The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures).
- Open Access
Drugs, Active Ingredients and Diseases Database in Spanish. Augmenting the Resources for Analyses on Drug–Illness Interactions
Quantitative and qualitative data on active-ingredient drug composition are essential information for characterizing near-field exposure of consumers to product-related chemicals, among other things. Equally as important is the characterization of the relationship between one or many active ingredients in terms of the diseases they are prescribed for. Such evaluations, however, require quantitative information at different anatomical levels. To complement the available sources of information on active substances and diseases, we have designed a database with enough versatility to potentially be used in a variety of analyzes. By using information provided by a well-established online pharmacological dictionary, we present a database with 11 tables which are easy to access and manipulate. Specifically, we present datasets containing the details of 12,827 marketed drug products, 40,164 diseases, 6231 active pharmaceutical ingredients and 4093 side effects. We exemplify the usefulness of our database with three simple visualizations, which confirm the importance of the data for quantifying the complexity in the associations among active substances, diseases and side effects. Although there are databases with detailed information on active substances and diseases, none of them can be found in Spanish. Our work presents an option that contributes substantially to obtaining well classified information in order to evaluate the roles of active pharmaceutical ingredients, diseases and side effects. These datasets also provide information about clinical and pharmacological groupings which may be useful for clinical and academic researchers. The database will be regularly updated and extended with the newly available Virtual Medicinal Products.
Open AccessDrugs, Active Ingredients and Diseases Database in Spanish. Augmenting the Resources for Analyses on Drug–Illness Interactions
Quantitative and qualitative data on active-ingredient drug composition are essential information for characterizing near-field exposure of consumers to product-related chemicals, among other things. Equally as important is the characterization of the relationship between one or many active ingredients in terms of the diseases they are prescribed for. Such evaluations, however, require quantitative information at different anatomical levels. To complement the available sources of information on active substances and diseases, we have designed a database with enough versatility to potentially be used in a variety of analyzes. By using information provided by a well-established online pharmacological dictionary, we present a database with 11 tables which are easy to access and manipulate. Specifically, we present datasets containing the details of 12,827 marketed drug products, 40,164 diseases, 6231 active pharmaceutical ingredients and 4093 side effects. We exemplify the usefulness of our database with three simple visualizations, which confirm the importance of the data for quantifying the complexity in the associations among active substances, diseases and side effects. Although there are databases with detailed information on active substances and diseases, none of them can be found in Spanish. Our work presents an option that contributes substantially to obtaining well classified information in order to evaluate the roles of active pharmaceutical ingredients, diseases and side effects. These datasets also provide information about clinical and pharmacological groupings which may be useful for clinical and academic researchers. The database will be regularly updated and extended with the newly available Virtual Medicinal Products.